BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23355559)

  • 1. Successful treatment of resistant SAPHO syndrome with anti-TNF therapy.
    Hampton SL; Youssef H
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23355559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature.
    Moll C; Hernández MV; Cañete JD; Gómez-Puerta JA; Soriano A; Collado A; Sanmartí R
    Semin Arthritis Rheum; 2008 Apr; 37(5):299-306. PubMed ID: 17976692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lobster sign in SAPHO syndrome: unusually extensive osteitis of the anterior chest wall partially responsive to infliximab.
    Anić B; Padjen I; Barešić M; Težak S
    Rheumatol Int; 2014 Feb; 34(2):281-2. PubMed ID: 23263495
    [No Abstract]   [Full Text] [Related]  

  • 4. The 'hidden' SAPHO syndrome.
    Carr F
    BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24473422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate.
    De Souza A; Solomon GE; Strober BE
    Bull NYU Hosp Jt Dis; 2011; 69(2):185-7. PubMed ID: 22035400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [SAPHO syndrome].
    Heldmann F; Kiltz U; Baraliakos X; Braun J
    Z Rheumatol; 2014 Oct; 73(8):729-41. PubMed ID: 25260820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor-alpha blockers in SAPHO syndrome.
    Ben Abdelghani K; Dran DG; Gottenberg JE; Morel J; Sibilia J; Combe B
    J Rheumatol; 2010 Aug; 37(8):1699-704. PubMed ID: 20472920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations.
    Massara A; Cavazzini PL; Trotta F
    Rheumatology (Oxford); 2006 Jun; 45(6):730-3. PubMed ID: 16403830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab.
    Iqbal M; Kolodney MS
    J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S118-20. PubMed ID: 15858507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab treatment for SAPHO syndrome.
    Arias-Santiago S; Sanchez-Cano D; Callejas-Rubio JL; Fernández-Pugnaire MA; Ortego-Centeno N
    Acta Derm Venereol; 2010 May; 90(3):301-2. PubMed ID: 20526553
    [No Abstract]   [Full Text] [Related]  

  • 11. Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism.
    Sabugo F; Liberman C; Niedmann JP; Soto L; Cuchacovich M
    Clin Rheumatol; 2008 Apr; 27(4):533-5. PubMed ID: 17938987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of ultrasonography in synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome: A case report.
    Asano T; Furuya MY; Fujita Y; Matsuoka N; Sato S; Kobayashi H; Watanabe H; Honda A; Migita K
    Medicine (Baltimore); 2018 Oct; 97(41):e12725. PubMed ID: 30313072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics of pediatric synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome: the first Chinese case series from a single center.
    Wu N; Shao Y; Huo J; Zhang Y; Cao Y; Jing H; Zhang F; Yu C; Yu Y; Li C; Song H; Zhang W
    Clin Rheumatol; 2021 Apr; 40(4):1487-1495. PubMed ID: 32929648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of a childhood synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome with subcutaneous methotrexate: A case report.
    Akçaboy M; Bakkaloğlu-Ezgü SA; Büyükkaragöz B; Isıyel E; Kandur Y; Hasanoğlu E; Buyan N
    Turk J Pediatr; 2017; 59(2):184-188. PubMed ID: 29276872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gingival pustules and sterile diffuse sclerosing osteomyelitis as a feature of synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome.
    Chou A; Schulman JM; Gross AJ; Jordan RC; Ramos DM
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 May; 121(5):e116-22. PubMed ID: 26619759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologics for rare inflammatory diseases: TNF blockade in the SA PHO syndrome.
    Burgemeister LT; Baeten DL; Tas SW
    Neth J Med; 2012 Dec; 70(10):444-9. PubMed ID: 23230013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAPHO syndrome in childhood. A case report.
    Vargas Pérez M; Sevilla Pérez B
    Reumatol Clin (Engl Ed); 2018; 14(2):109-112. PubMed ID: 27993538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAPHO syndrome presenting as septic arthritis in the hip.
    O'Connor DA; Ridha H; Roche CJ; O'Sullivan M
    Ir Med J; 2003 Feb; 96(2):41-2. PubMed ID: 12674151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of SAPHO syndrome with apremilast.
    Adamo S; Nilsson J; Krebs A; Steiner U; Cozzio A; French LE; Kolios AGA
    Br J Dermatol; 2018 Oct; 179(4):959-962. PubMed ID: 29034454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SAPHO syndrome in an adolescent: a clinical case with unusual severe systemic impact.
    Freira S; Fonseca H; Ferreira PD; Vasconcelos P; Fonseca JE
    J Adolesc Health; 2014 Aug; 55(2):304-6. PubMed ID: 24726464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.